Home › Acute Myeloid Leukemia › Michigan

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Michigan

24 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Michigan.

Mga Lungsod sa Michigan

Opisyal na teksto ng pag-aaral (English)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
at 3 pa

Nagre-recruitPhase 2

Edad 60 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07437950

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
at 6 pa

Nagre-recruitPhase 2

Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Henry Ford Health System, Detroit
Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
at 14 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor

Nagre-recruitPhase 1

Hanggang edad 21 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07012044

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
at 11 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06672146

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
at 6 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
at 9 pa

Nagre-recruitPhase 2

Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
at 1 pa

Nagre-recruitPhase 3

6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

START Midwest, Grand Rapids

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

Nagre-recruitPhase 3

Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07022678

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
at 71 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
at 2 pa

Nagre-recruitPhase 1/2

Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

C.S. Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit

Nagre-recruitPhase 3

29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Karmanos Cancer Institute, Detroit
Henry Ford Cancer Institute, Detroit

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Michigan, Ann Arbor
Wayne State University School of Medicine, Detroit

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

START Midwest, Grand Rapids

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT07751991

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Henry Ford Cancer Institute, Detroit

Nagre-recruitPhase 3

Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Michigan, Ann Arbor
Children's Hospital of Michigan, Detroit
Henry Ford Health System, Detroit
at 2 pa

Nagre-recruitObservasyonal na pag-aaral

Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

University of Michigan, Ann Arbor

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT05768932

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2026 · NCT02269592

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Karmanos Cancer Institute, Detroit

Nagre-recruitPhase 2

Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

Nagre-recruitObservasyonal na pag-aaral

Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 28, 2025 · NCT07145411

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.